XORTX regains Nasdaq compliance after reverse stock split

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. TECHM:IN
10. NVDA

Go back to XORTX regains Nasdaq compliance after reverse stock split

XORTX Meets Nasdaq Continued Listing Requirements

April 21, 2026 7:00 AM EDT

CALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that it has received a letter of compliance from the Nasdaq Stock Market LLCs ("Nasdaq) Listing Qualifications Department in connection with Nasdaq Rule 5550(a)(2) that requires a listed companys shares to maintain a minimum bid price of US$1.00 per share (the Minimum Bid Requirement). In order to... More